Celcuity Inc
CELC54.600USD
+1.530+2.88%
종가 09/17, 16:00（ET）시세는 15분 지연됩니다
2.12B시가총액
손실P/E TTM
자세한 내용은 Celcuity Inc 회사
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.
회사 정보
종목 코드 CELC
회사 이름Celcuity Inc
상장일Sep 20, 2017
CEOMr. Brian F. Sullivan
직원 수87
유형Ordinary Share
회계 연도 종료Sep 20
주소16305 36th Ave N Ste 100
도시MINNEAPOLIS
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호55446-4285
전화17633920767
웹사이트https://www.celcuity.com/
종목 코드 CELC
상장일Sep 20, 2017
CEOMr. Brian F. Sullivan
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.13M
+3.45%
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
109.01K
+7.83%
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
18.86K
+1.63%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
7.71K
-0.64%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
5.00K
--
Dr. Lance G. Laing, Ph.D.
Dr. Lance G. Laing, Ph.D.
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
--
--
Mr. David F. Dalvey
Mr. David F. Dalvey
Independent Director
Independent Director
--
--
Dr. Charlotte Moser, M.D., Ph.D.
Dr. Charlotte Moser, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Leo T. Furcht, M.D.
Dr. Leo T. Furcht, M.D.
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.13M
+3.45%
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
109.01K
+7.83%
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
18.86K
+1.63%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
7.71K
-0.64%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
5.00K
--
Dr. Lance G. Laing, Ph.D.
Dr. Lance G. Laing, Ph.D.
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Sun, Aug 31
마지막 업데이트: Sun, Aug 31
주주
주주 유형
주주
주주
비율
Baker Bros. Advisors LP
18.66%
BVF Partners L.P.
8.17%
Sullivan (Brian F)
7.38%
Soleus Capital Management, L.P.
7.10%
Perceptive Advisors LLC
6.29%
기타
52.40%
주주
주주
비율
Baker Bros. Advisors LP
18.66%
BVF Partners L.P.
8.17%
Sullivan (Brian F)
7.38%
Soleus Capital Management, L.P.
7.10%
Perceptive Advisors LLC
6.29%
기타
52.40%
주주 유형
주주
비율
Hedge Fund
42.18%
Investment Advisor
19.01%
Individual Investor
11.21%
Investment Advisor/Hedge Fund
7.74%
Venture Capital
6.52%
Private Equity
6.33%
Research Firm
2.10%
Corporation
0.82%
Pension Fund
0.08%
기타
3.99%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
214
35.30M
87.21%
-4.75M
2025Q1
215
36.05M
95.22%
-4.12M
2024Q4
205
35.54M
95.72%
-3.01M
2024Q3
191
34.97M
94.40%
-1.82M
2024Q2
174
33.96M
98.53%
+4.98M
2024Q1
164
26.84M
87.18%
+3.25M
2023Q4
146
21.83M
92.28%
-1.69M
2023Q3
148
21.82M
100.72%
+289.20K
2023Q2
156
20.45M
95.00%
-276.65K
2023Q1
152
18.61M
87.60%
-1.61M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Baker Bros. Advisors LP
4.26M
11.24%
+1.58M
+58.96%
Mar 31, 2025
BVF Partners L.P.
3.47M
9.15%
--
--
Mar 31, 2025
Sullivan (Brian F)
3.02M
7.99%
+8.15K
+0.27%
Apr 14, 2025
Soleus Capital Management, L.P.
2.57M
6.8%
+9.04K
+0.35%
Mar 31, 2025
Perceptive Advisors LLC
2.36M
6.24%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
1.25M
3.3%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.03M
5.35%
+10.04K
+0.50%
Mar 31, 2025
The Vanguard Group, Inc.
1.67M
4.42%
+20.26K
+1.23%
Mar 31, 2025
Eventide Asset Management, LLC
1.27M
3.34%
--
--
Mar 31, 2025
Laing (Lance G Ph.D.)
1.25M
3.3%
--
--
Mar 17, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Sep 6
마지막 업데이트: Sat, Sep 6
이름
비율
Innovator US Small Cap Managed Floor ETF
0%
Direxion Daily S&P Biotech Bull 3X Shares
0%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
Avantis US Small Cap Equity ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
iShares Morningstar Small-Cap ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
ProShares Hedge Replication ETF
0%
SPDR S&P Biotech ETF
0%
Humankind US Stock ETF
0%
더 보기
Innovator US Small Cap Managed Floor ETF
비율0%
Direxion Daily S&P Biotech Bull 3X Shares
비율0%
Invesco Russell 2000 Dynamic Multifactor ETF
비율0%
Avantis US Small Cap Equity ETF
비율0%
Invesco Dorsey Wright SmallCap Momentum ETF
비율0%
iShares Morningstar Small-Cap ETF
비율0%
DFA Dimensional US Sustainability Core 1 ETF
비율0%
ProShares Hedge Replication ETF
비율0%
SPDR S&P Biotech ETF
비율0%
Humankind US Stock ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
